Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 5
2004 6
2006 6
2007 3
2008 1
2009 7
2010 3
2011 6
2012 5
2013 4
2014 8
2015 4
2016 11
2017 7
2018 8
2019 17
2020 15
2021 10
2022 6
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Prostate Carcinoma by Gene Expression Profile"
Page 1
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, Easton A, Yee-Toy NC, Chen FZ, Gorlatov S, Barat B, Huang L, Wolff CR, Hooley J, Hotaling TE, Gaynutdinov T, Ciccarone V, Tamura J, Koenig S, Moore PA, Bonvini E, Loo D. Scribner JA, et al. Mol Cancer Ther. 2020 Nov;19(11):2235-2244. doi: 10.1158/1535-7163.MCT-20-0116. Epub 2020 Sep 23. Mol Cancer Ther. 2020. PMID: 32967924
B7-H3, also referred to as CD276, is a member of the B7 family of immune regulatory proteins. B7-H3 is overexpressed on many solid cancers, including prostate cancer, renal cell carcinoma, melanoma, squamous cell carcinoma of the head and neck, non-small cell …
B7-H3, also referred to as CD276, is a member of the B7 family of immune regulatory proteins. B7-H3 is overexpressed on many solid cancers, …
The value of biomarkers in bone metastasis.
D'Oronzo S, Brown J, Coleman R. D'Oronzo S, et al. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12725. Epub 2017 Jun 27. Eur J Cancer Care (Engl). 2017. PMID: 28653449 Review.
In particular, bone provides a fertile soil for several cancer types, especially those derived from breast, prostate and lung tumours. Despite the progress in diagnostic and therapeutic strategies, bone metastases (BM) still impact on quality of life and overall survival, …
In particular, bone provides a fertile soil for several cancer types, especially those derived from breast, prostate and lung tumours …
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG. Feng E, et al. Clin Cancer Res. 2022 Dec 15;28(24):5396-5404. doi: 10.1158/1078-0432.CCR-22-2567. Clin Cancer Res. 2022. PMID: 36260524 Free PMC article.
PURPOSE: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts. Thus …
PURPOSE: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer …
Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z, Cheng X, Yue T, Shangguan X, Xin Z, Zhang W, Pan J, Wang Q, Xue W. Ma Z, et al. Cancer Med. 2021 Aug;10(15):5358-5374. doi: 10.1002/cam4.4063. Epub 2021 Jun 15. Cancer Med. 2021. PMID: 34128342 Free PMC article.
METHODS: Herein, we investigated the immune infiltration phenotypes in PRAD based on transcriptome profiles, methylation profiles, somatic mutation, and copy number variations. ...Besides, we constructed a nomogram incorporating Gleason score, pathological T stage, …
METHODS: Herein, we investigated the immune infiltration phenotypes in PRAD based on transcriptome profiles, methylation profiles, so …
The role of mir-151a-5p in tumorigenesis; A systematic review.
Ebrahimi A, Derakhshan SM, Ghavi D, Foruzandeh Z, Hashemi S. Ebrahimi A, et al. Pathol Res Pract. 2023 Sep;249:154576. doi: 10.1016/j.prp.2023.154576. Epub 2023 Jun 1. Pathol Res Pract. 2023. PMID: 37562284 Review.
RESULTS: Assembled data indicate the expression levels of mir-151a-5p vary from down- to up-regulated based on the type of the cancer. Its functional role depends on the genetic profile of cancerous tissue. Results mostly point to the oncogenic role of this miRNA in …
RESULTS: Assembled data indicate the expression levels of mir-151a-5p vary from down- to up-regulated based on the type of the cancer …
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.
Ye B, Shi J, Kang H, Oyebamiji O, Hill D, Yu H, Ness S, Ye F, Ping J, He J, Edwards J, Zhao YY, Guo Y. Ye B, et al. RNA Biol. 2020 Nov;17(11):1666-1673. doi: 10.1080/15476286.2019.1679585. Epub 2019 Oct 18. RNA Biol. 2020. PMID: 31607216 Free PMC article.
One of the most robust approaches to demonstrate non-coding RNA's biological relevance is through their prognostic value. Using the rich gene expression data from The Cancer Genome Altas (TCGA), we designed Advanced Expression Survival Analysis (AESA), a web …
One of the most robust approaches to demonstrate non-coding RNA's biological relevance is through their prognostic value. Using the rich …
Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M, Tota D, Giorcelli J, Bollito E, Napoli F, Vatrano S, Buttigliero C, Molinaro L, Gontero P, Porpiglia F, Tucci M, Papotti M, Berruti A, Rapa I. Volante M, et al. Hum Pathol. 2016 Oct;56:81-8. doi: 10.1016/j.humpath.2016.06.004. Epub 2016 Jun 21. Hum Pathol. 2016. PMID: 27342909
The correlation between biopsy and surgical samples was poor for most of the tested genes. Gene expression analysis of separate tumor areas from the same patient showed an extremely heterogeneous profile in the 6 tested cases (all untreated). ...However, intr …
The correlation between biopsy and surgical samples was poor for most of the tested genes. Gene expression analysis of separat …
The androgen receptor malignancy shift in prostate cancer.
Copeland BT, Pal SK, Bolton EC, Jones JO. Copeland BT, et al. Prostate. 2018 May;78(7):521-531. doi: 10.1002/pros.23497. Epub 2018 Feb 23. Prostate. 2018. PMID: 29473182 Review.
RESULTS: In benign prostate epithelial cells, the AR primarily binds consensus AR binding sites. ...Current evidence suggests that the AR malignancy shift is necessary but not sufficient for transformation of prostate epithelial cells. CONCLUSIONS: Reinterpretation …
RESULTS: In benign prostate epithelial cells, the AR primarily binds consensus AR binding sites. ...Current evidence suggests that th …
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Han H, Lee HH, Choi K, Moon YJ, Heo JE, Ham WS, Jang WS, Rha KH, Cho NH, Giancotti FG, Choi YD. Han H, et al. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1080-1092. doi: 10.1038/s41391-021-00364-x. Epub 2021 Apr 26. Prostate Cancer Prostatic Dis. 2021. PMID: 33903734 Free PMC article.
Serum markers PSA and PAP was analyzed to predict response to docetaxel chemotherapy in metastatic setting. ...Luminal A and AVPC-M predicted to be resistant to docetaxel and have high PSA/PAP Ratio. ...
Serum markers PSA and PAP was analyzed to predict response to docetaxel chemotherapy in metastatic setting. ...Luminal A and AVPC-M …
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
Bae SY, Bergom HE, Day A, Greene JT, Sychev ZE, Larson G, Corey E, Plymate SR, Freedman TS, Hwang JH, Drake JM. Bae SY, et al. Front Endocrinol (Lausanne). 2023 Mar 29;14:1093332. doi: 10.3389/fendo.2023.1093332. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37065756 Free PMC article.
NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results in resistance to AR-targeted therapy. NEPC resembles other SCN carcinomas clinically, histologically and in ge …
NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenot …
125 results